Cartalax
Muscle/RecoveryKhavinson bioregulator / researchExperimental
Short peptide marketed for cartilage/connective-tissue bioregulator research. Not FDA-approved.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 317.3 g/mol
- Half-life
- Short (hours)
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Daily
- Last updated
- 8/23/2026
- Targets
- Chondrocytes (proposed)
Overview
Short peptide marketed for cartilage/connective-tissue bioregulator research. Not FDA-approved.
Protocol
- Dosage Range
- 2-5 mg per day
- Frequency
- Daily
- Cycle
- 4-6 weeks on, 4-6 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 3 mL BAC water for 25 mg vial
Science
Mechanism of Action
Proposed to influence chondrocyte protein synthesis in Khavinson-series papers. Controlled clinical evidence is lacking.
Targets
Chondrocytes (proposed)
Studies
- Peptide bioregulators overview— Journal/year not available
Benefits
Connective-tissue bioregulator research
Potential Side Effects
- Not well characterized
References
- PMID 15587334External link · Year —